JPMorgan's Take on Roivant Sciences (ROIV) Buyback and Positive Data Annoucement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Truist Securities sees Roivant Sciences (ROIV) shares up today on positive brepocitinib data
April 2, 2024 8:04 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $23.00 price target on Roivant Sciences (NASDAQ: ROIV), saying positive brepocitinib data supports potential success in NIU.
The analyst commented, "We believe Roivant shares could be up today following announcement of positive Ph2 results for... More
Roivant Sciences (ROIV) Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback
April 2, 2024 7:02 AM EDTRoivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the companys common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivants shares outstanding as of February 9, 2024... More
